The Moderna vaccine involves "no further mixing or dilution, while remaining stable for up to 12 hours at room temperature," Moderna’s Chief Medical Officer, Dr. Tal Zaks, said on Thursday.
During the Vaccines and Related Biological Products Advisory Committee (VRBPAC), Zaks said the manufacturing process "does not use products of animal or human origin, and it does not contain preservatives or adjuvants."
The Phase 3 study shows "the vaccine efficacy rate for symptomatic Covid-19 infection was 94.1%, with a 95% confidence interval lower bound of 89.3%," Zaks said.
"Importantly, we also observed a dramatic reduction in severe cases. All of the 30 severe cases observed at the time of primary analysis occurred in people given placebo," Zaks added.
Moderna says that a reduction in symptomatic cases "predicts a reduction in cases leading to hospitalization, intensive care and death."
Moderna has done early phase clinical trials on infectious disease for several years, Zaks said. "We have had not seen a significant safety concern in any of our trials to date."